Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH 45267-0525, USA.
Division of Hematology & Oncology, Department of Internal Medicine, 3125 Eden Avenue, ML 0562, Cincinnati, OH 45219-0562, USA.
Biomolecules. 2023 Feb 17;13(2):381. doi: 10.3390/biom13020381.
Cardiopulmonary complications remain the major cause of mortality despite newer therapies and improvements in the lifespan of patients with sickle cell disease (SCD). Inflammation has been identified as a major risk modifier in the pathogenesis of SCD-associated cardiopulmonary complications in recent mechanistic and observational studies. In this review, we discuss recent cellular and molecular mechanisms of cardiopulmonary complications in SCD and summarize the most recent evidence from clinical and laboratory studies. We emphasize the role of inflammation in the onset and progression of these complications to better understand the underlying pathobiological processes. We also discuss future basic and translational research in addressing questions about the complex role of inflammation in the development of SCD cardiopulmonary complications, which may lead to promising therapies and reduce morbidity and mortality in this vulnerable population.
尽管有更新的疗法和患者寿命的改善，镰状细胞病（SCD）患者的心肺并发症仍然是主要的死亡原因。在最近的机制和观察研究中，炎症已被确定为 SCD 相关心肺并发症发病机制中的主要风险修饰因子。在这篇综述中，我们讨论了 SCD 中心肺并发症的最新细胞和分子机制，并总结了来自临床和实验室研究的最新证据。我们强调了炎症在这些并发症发生和进展中的作用，以更好地理解潜在的病理生理过程。我们还讨论了未来基础和转化研究，以解决炎症在 SCD 心肺并发症发展中复杂作用的相关问题，这可能会带来有前途的治疗方法，并降低这一脆弱人群的发病率和死亡率。
